Edition:
India

Profile: Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

11.47USD
15 Dec 2017
Change (% chg)

$0.05 (+0.44%)
Prev Close
$11.42
Open
$11.45
Day's High
$11.92
Day's Low
$11.41
Volume
105,373
Avg. Vol
195,281
52-wk High
$25.95
52-wk Low
$5.42

Zynerba Pharmaceuticals, Inc., incorporated on January 31, 2007, is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001.

ZYN002

ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome.

ZYN001

ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

The Company competes with GW Pharmaceuticals, PLC, Insys Therapeutics, Inc., Kalytera Therapeutics, Inc., Neuren Pharmaceuticals, Meda AB and Marinus Pharmaceuticals.

Company Address

Zynerba Pharmaceuticals Inc

80 W. Lancaster Avenue, Suite 30
DEVON   PA   19333
P: +1484.5817505
F: +1302.6555049

Company Web Links